CredoScientia - Bibliothèque

Expanding Policy and Programming to Address Conversion Therapy and 2SLGBTQ+ Health Inequity: A Discussion of Challenges.

Advocates and researchers have made myriad recommendations to guide policy actors in stopping conversion therapy. This commentary extends these recommendations by identifying core challenges that poli…

Thérapies de Conversion

Kinitz, D. J., Tran, N. K., & MacKinnon, K. R. (2024). Expanding Policy and Programming to Address Conversion Therapy and 2SLGBTQ+ Health Inequity: A Discussion of Challenges.. Healthc Pap, 22(1), 46-54. https://doi.org/10.12927/hcpap.2024.27386

01/04/2024 Lire →

Beyond the Rainbow: Advancing 2S/LGBTQ+ Health Equity at a Time of Political Volatility.

Two-Spirit, lesbian, gay, bisexual, transgender, queer and other sexual and gender minority (2S/LGBTQ+) populations continue to experience profound health disparities. In this article, we prioritize f…

Thérapies de Conversion

Kia, H., Robinson, M., Lee, E. O. J., Salway, T., & Ross, L. E. (2024). Beyond the Rainbow: Advancing 2S/LGBTQ+ Health Equity at a Time of Political Volatility.. Healthc Pap, 22(1), 9-25. https://doi.org/10.12927/hcpap.2024.27390

01/04/2024 Lire →

Current controversies in glia-to-neuron conversion therapy in neurodegenerative diseases.

Thérapies de Conversion

Cao, P., Li, J., Liu, Z., & Liang, G. (2024). Current controversies in glia-to-neuron conversion therapy in neurodegenerative diseases.. Neural Regen Res, 19(4), 723-724. https://doi.org/10.4103/1673-5374.382251

01/04/2024 Lire →

[Advancements and controversies in conversion therapy for biliary tract malignant tumors with insufficient future liver remnant].

Due to the unique location and aggressive tumor biology,hilar cholangiocarcinoma,intrahepatic cholangiocarcinoma,and gallbladder cancer often present with obstructive jaundice and require extensive li…

Thérapies de Conversion

Wang, Z., & Hong, D. F. (2024). [Advancements and controversies in conversion therapy for biliary tract malignant tumors with insufficient future liver remnant].. Zhonghua Wai Ke Za Zhi, 62(4), 284-289. https://doi.org/10.3760/cma.j.cn112139-20231218-00283

01/04/2024 Lire →

Liver-directed moderately hypo-fractionated radiotherapy combined with pembrolizumab and bevacizumab for advanced hepatocellular carcinoma: a retrospective observational study of 23 cases.

BACKGROUND: Programmed cell death protein 1 (PD-1) or its ligand (PD-L1) monoclonal antibody combined with bevacizumab (a monoclonal antibody targeting vascular endothelial growth factor) has been est…

Thérapies de Conversion

Liang, X., Jiang, Y., Yao, W., Deng, Y., Yang, S., & Liu, Q. (2024). Liver-directed moderately hypo-fractionated radiotherapy combined with pembrolizumab and bevacizumab for advanced hepatocellular carcinoma: a retrospective observational study of 23 cases.. Transl Cancer Res, 13(3), 1508-1518. https://doi.org/10.21037/tcr-23-1333

31/03/2024 Lire →

Posterior and Para-Aortic (D2plus) Lymphadenectomy after Neoadjuvant/Conversion Therapy for Locally Advanced/Oligometastatic Gastric Cancer.

Super-extended (D2plus) lymphadenectomy after chemotherapy has been reported in only a few studies. This retrospective study evaluates survival outcomes in a Western cohort of locally advanced or olig…

Thérapies de Conversion

Marrelli, D., Piccioni, S. A., Carbone, L., Petrioli, R., Costantini, M., Malagnino, V., Bagnacci, G., Rizzoli, G., Calomino, N., Piagnerelli, R., Mazzei, M. A., & Roviello, F. (2024). Posterior and Para-Aortic (D2plus) Lymphadenectomy after Neoadjuvant/Conversion Therapy for Locally Advanced/Oligometastatic Gastric Cancer.. Cancers (Basel), 16(7). https://doi.org/10.3390/cancers16071376

31/03/2024 Lire →

Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate.

The high mortality rate in hepatocellular carcinoma (HCC) is partially due to the fact that a significant number of patients are diagnosed at an intermediate or advanced stage, with surgical treatment…

Thérapies de Conversion

Chen, Q. F., Chen, S., Chen, M., Lyu, N., & Zhao, M. (2024). Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate.. J Clin Transl Hepatol, 12(3), 298-304. https://doi.org/10.14218/JCTH.2023.00403

28/03/2024 Lire →

Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics.

Therapies for patients with unresectable hepatocellular carcinoma (uHCC) are currently popular. Current first-line standard-of-care treatments for uHCC are systematic therapies. However, treatments th…

Thérapies de Conversion

Wu, J., Wu, J., Li, S., Luo, M., Zeng, Z., Li, Y., Fu, Y., Li, H., Liu, D., Ou, X., Lin, Z., Wei, S., & Yan, M. (2024). Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics.. Biosci Trends, 18(1), 42-48. https://doi.org/10.5582/bst.2023.01326

19/03/2024 Lire →

Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy.

Pulmonary blastomas (PB) are an extremely rare type of lung cancer. Currently, no standard treatment exists for PB. Immunotherapy with checkpoint inhibitors and anti-angiogenesis treatments has been a…

Thérapies de Conversion

Chen, Y., Chen, H., Yu, R., Zeng, X., Tian, D., Pu, Q., & Liu, Y. (2024). Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy.. Lung Cancer, 189, 107476. https://doi.org/10.1016/j.lungcan.2024.107476

01/03/2024 Lire →

Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study.

BACKGROUND: Data on the long-term oncological outcomes of patients who undergo conversion surgery (CS) in gastric cancer (GC) patients with peritoneal metastasis (PM) are limited.METHODS: GC patients …

Thérapies de Conversion

Yang, Z., Lu, S., Shi, M., Yuan, H., Wang, Z., Ni, Z., He, C., Zheng, Y., Zhu, Z., Liu, W., Yao, X., Zhang, J., Li, C., Yan, M., Yan, C., & Zhu, Z. (2024). Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study.. Gastric Cancer, 27(2), 387-399. https://doi.org/10.1007/s10120-023-01452-8

01/03/2024 Lire →

[Real-World Efficacy and Safety of China-Made Flumatinib Mesylate in the Treatment of Chronic Myeloid Leukemia in Chronic Phase].

OBJECTIVE: To evaluate the efficacy and safty of China-made flumatinib mesylate in the treatment of chronic myeloid leukemia in chronic phase (CML-CP).METHODS: 42 CML-CP patients treated with Chinese …

Thérapies de Conversion

Li, Y. Y., & Wang, C. L. (2024). [Real-World Efficacy and Safety of China-Made Flumatinib Mesylate in the Treatment of Chronic Myeloid Leukemia in Chronic Phase].. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 32(1), 14-19. https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.01.004

01/02/2024 Lire →

Conversion therapy for initially unresectable hepatocellular carcinoma: Current status and prospects.

Research has shown that locoregional and/or systemic treatments can reduce the tumor stage, enabling radical surgical resection in patients with initially unresectable hepatocellular carcinoma. This i…

Thérapies de Conversion

Ma, Y. N., Jiang, X., Liu, H., Song, P., & Tang, W. (2024). Conversion therapy for initially unresectable hepatocellular carcinoma: Current status and prospects.. Biosci Trends, 17(6), 415-426. https://doi.org/10.5582/bst.2023.01322

30/01/2024 Lire →